Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Lisata Therapeutics Inc Market Cap
The Lisata Therapeutics Inc (LSTA) share price is expected to increase by 416.61% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered LSTA. Price targets range from $13 at the low end to $15 at the high end. The current analyst consensus for LSTA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
LSTA is a stock in Healthcare which has been forecasted to be worth $14 as an average. On the higher end, the forecast price is $15 USD by Joseph Pantginis from HC Wainwright & Co. and on the lower end LSTA is forecasted to be $13 by from .
These are the latest 20 analyst ratings of LSTA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Nov 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Sep 18, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Aug 13, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Jul 19, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Jul 10, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Jun 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | May 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Apr 26, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Apr 25, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Mar 1, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Jan 4, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Aug 15, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | May 25, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Reiterates | Mar 31, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $15 | Maintains | Oct 19, 2022 |
When did it IPO
N/A
Staff Count
25
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Market Cap
$23.2M
In 2023, LSTA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that LSTA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Dec 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Lisata Therapeutics (NASDAQ:LSTA) has partnered with Kuva Labs to provide access to its certepetide for developing advanced MR imaging agents targeting solid tumors.
Why It Matters - The collaboration enhances Lisata's pipeline and potential revenue through innovative cancer imaging, signaling growth prospects that could attract investor interest and impact stock performance.
Tue, 19 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Lisata Therapeutics Inc (NASDAQ:LSTA) was named 'Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards for its CendR Platform targeting advanced solid tumors.
Why It Matters - Lisata Therapeutics' award highlights its innovative technology in cancer treatment, potentially boosting its market position and attractiveness to investors focused on biotech advancements.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Lisata has received an award for its data-driven approach and innovative therapies targeting unmet medical needs in patients with advanced solid tumors.
Why It Matters - Lisata's recognition highlights its potential for growth in the oncology sector, signaling to investors that its innovative therapies may lead to increased market share and revenue opportunities.
Sat, 16 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo announced progress in its pancreatic cancer ASCEND trial and discussed the company's Q3 financial performance in a recent interview.
Why It Matters - Advancements in Lisata's pancreatic cancer program and upcoming ASCEND trial data could significantly impact stock valuation and investor sentiment regarding the company's future potential.
Tue, 12 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Lisata Therapeutics (NASDAQ:LSTA) reported key clinical advancements in Q3, with multiple data readouts expected in 18 months. Operating expenses decreased 10.5% YoY to $5.3 million.
Why It Matters - Lisata's clinical advancements and reduced operating expenses indicate potential for growth and improved profitability, which could enhance investor confidence and stock performance.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Lisata Therapeutics, Inc. (NASDAQ:LSTA) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key executives and financial updates.
Why It Matters - The upcoming earnings call for Lisata Therapeutics will provide insights into the company's financial health and strategic direction, influencing investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
